- Home
- TVRD
TVRD
Tvardi Therapeutics Inc. Common Stock
as 11-04-2025 1:30pm EST
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SUGAR LAND |
| Market Cap: | 246.5M | IPO Year: | N/A |
| Target Price: | $51.67 | AVG Volume (30 days): | 716.6K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.48 - $43.65 | Next Earning Date: | 11-21-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tvardi Therapeutics Inc. Common Stock News
TVRD Breaking Stock News: Dive into TVRD Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
Zacks
21 days ago
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
BioPharma Dive
21 days ago
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance
Simply Wall St.
21 days ago
Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results
MT Newswires
22 days ago
Top Midday Decliners
MT Newswires
22 days ago
Barclays Initiates Tvardi Therapeutics at Overweight With $61 Price Target
MT Newswires
22 days ago
Sector Update: Health Care Stocks Higher Premarket Monday
MT Newswires
22 days ago
Tvardi Therapeutics' Potential Lung Disease Treatment Fails to Meet Goals; Shares Decline Pre-Bell
Compare TVRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVRD Tvardi Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.